Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.39 USD
-0.31 (-2.26%)
Updated Jan 31, 2025 04:00 PM ET
After-Market: $13.38 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TAK 13.39 -0.31(-2.26%)
Will TAK be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?
TAK or CTLT: Which Is the Better Value Stock Right Now?
Other News for TAK
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy Rating
Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Takeda Pharmaceutical Non-GAAP EPS of ¥443.00, revenue of ¥3528.2B; raises FY outlook
Alumis draws Outperform at Oppenheimer on valuation disconnect